<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116269</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB MED CT4 10-239</org_study_id>
    <nct_id>NCT03116269</nct_id>
  </id_info>
  <brief_title>The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients</brief_title>
  <acronym>PASS</acronym>
  <official_title>The Effect of Cilostazol Compared to Aspirin on Endothelial Function Measured by Flow Mediated Dilatation in Acute Cerebral Ischemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting with acute cerebral ischemic events are randomly assigned into aspirin
      (n=40) or cilostazol (n=40) group in a double-blinded manner. FMD is measured as a primary
      outcome at baseline (T0) and 90 days (T1). Serious and non-serious adverse events were
      described.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigator-initiated, randomized, double-blind trial is prospectively conducted with
      two-arm parallel treatment groups and a single dose scheme: 100 mg aspirin daily and
      cilostazol placebo twice daily versus aspirin placebo daily and 100 mg cilostazol twice
      daily.

      A total of 80 eligible patients is planned to be recruited.

      All included patients undergo diagnostic studies including routine blood tests and
      cardiologic work-ups. The primary outcome is differences in endothelial function in the two
      groups measured by means of FMD on admission and at 3 months. According to previous studies,
      the adverse effects in two groups are investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2012</start_date>
  <completion_date type="Actual">October 31, 2014</completion_date>
  <primary_completion_date type="Actual">October 31, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>flow mediated dilation</measure>
    <time_frame>3 month change</time_frame>
    <description>flow mediated dilation of the brachial artery in response to hyperemia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>cilostazol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aspirin placebo daily and 100 mg cilostazol twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg aspirin daily and cilostazol placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol 100mg</intervention_name>
    <arm_group_label>cilostazol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>aspirin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. acute ischemic stroke confirmed by diffusion weighted imaging

          2. transient ischemic attack (TIA) within 7 days

        Exclusion Criteria:

          1. there is intracranial hemorrhage on imaging study

          2. patients is previously taking antiplatelets, vitamin K antagonists, factor Xa
             antagonists, or chronic treatment with systemic steroidal and non-steroidal
             anti-inflammatory drugs

          3. patients who received fibrinolytics within the previous 48 hours

          4. cognitive impairment interfering with the possibility of obtaining informed consent

          5. pregnancy

          6. participation in another pharmacological study

          7. peptic ulcer disease or hematological abnormality

          8. initial modified Barthel index &lt;30 points

          9. liver function tests exceeding a 2-fold upper range value.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Man Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>82 31 219 5174</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon</city>
        <state>Gyunggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ji Man Hong</investigator_full_name>
    <investigator_title>Associate proffessor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

